Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Personal Genome Service For Carrier Screening Emerges From 23andMe Work With FDA

This article was originally published in The Tan Sheet

Executive Summary

Two years of conversations with FDA lead 23andMe back to the health care market with the launch of its Personal Genome Service, focused on carrier screening tests. The firm says its close engagement with FDA improved its customer communication and quality control.


Related Content

FDA Warns DTC Genetic Test Firms
FDA, 23andMe Open Up Market Pathway For DTC Genetics
FDA Points To Premarket Clearance For Direct-To-Consumer Genetic Tests


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst